创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

李杨, 张文宏. 耐多药结核病治疗药物演变与新进展[J]. 药学进展, 2021, 45(6): 419-426.
引用本文: 李杨, 张文宏. 耐多药结核病治疗药物演变与新进展[J]. 药学进展, 2021, 45(6): 419-426.
LI Yang, ZHANG Wenhong. Updates of Anti-tuberculosis Drugs for the Treatment of Multidrug Resistant Tuberculosis[J]. Progress in Pharmaceutical Sciences, 2021, 45(6): 419-426.
Citation: LI Yang, ZHANG Wenhong. Updates of Anti-tuberculosis Drugs for the Treatment of Multidrug Resistant Tuberculosis[J]. Progress in Pharmaceutical Sciences, 2021, 45(6): 419-426.

耐多药结核病治疗药物演变与新进展

Updates of Anti-tuberculosis Drugs for the Treatment of Multidrug Resistant Tuberculosis

  • 摘要: 耐多药结核病(MDR-TB)是当前结核病实现有效防控的主要障碍。长期以来缺乏有效的药物组成治疗方案是MDR-TB防控困难的重要原因。肺结核的治疗以化学治疗为主,从早期链霉素、氟喹诺酮类药物的应用,到利奈唑胺、贝达喹啉、氯法齐明等药物的涌现,MDR-TB治疗药物经历了数十年的革新和发展。通过介绍MDR-TB国际治疗指南更新,讨论不同抗结核病药物的治疗特点、在MDR-TB治疗中的角色变迁以及在中国临床应用的前景。

     

    Abstract: Multidrug-resistant tuberculosis(MDR-TB) is the main obstacle to effective prevention and control of tuberculosis, due mainly to the long-term lack of effective drugs for the therapeutic regimen. Chemotherapy has been the fundamental approach to the treatment of tuberculosis, using streptomycin and fluoroquinolones at the beginning, then drugs such as linezolid, bedaquiline and clofazimine, with decades of years for the innovation and development in the treatment of multidrug-resistant tuberculosis. This article introduces the updated international treatment guidelines and discusses the treatment characteristics of different anti-tuberculosis drugs, their role changes in MDRTB treatment, and the prospects of their application in China.

     

/

返回文章
返回